BCL2 and plasma cell myeloma: Furthermore, the BCL2 inhibitor, venetoclax, is also a suitable option for patients with RRMM at first relapse with t(11;14) either as monotherapy or in combination with standard anti-myeloma agents such as daratumumab or carfilzomib; however, there are no published data from large phase 3 studies [77].